Design Therapeutics, Inc. (DSGN) vs Prime Medicine, Inc. (PRME)

Design Therapeutics, Inc. and Prime Medicine, Inc. are both Biotechnology companies. Design Therapeutics, Inc. and Prime Medicine, Inc. are of similar size ($655.9M and $654.8M). Design Therapeutics, Inc. has the higher net margin (0.00% vs −4,613.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Design Therapeutics, Inc. leads on 9 and Prime Medicine, Inc. on 5.

Valuation

Metric DSGN PRME Biotechnology median
P/E n/m n/m 8.50
P/S 2,851.44 150.99 9.71
P/B 3.19 15.45 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 1,933.76 127.65 9.21
Earnings yield (11.45%) (30.93%) (33.15%)
Free cash flow yield (8.57%) (25.50%) (25.50%)

Profitability

Metric DSGN PRME Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (4,824.94%) 0.00%
Net margin 0.00% (4,613.11%) 0.00%
Free cash flow margin 0.00% (3,850.92%) 0.00%
Return on equity (34.13%) (373.29%) (56.36%)
Return on assets (32.33%) (71.16%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric DSGN PRME Biotechnology median
Revenue growth (TTM) — (17.90%) 6.02%
EPS growth (last fiscal year) (38.64%) 18.18% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DSGN PRME Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 18.86 3.05 4.72
Net debt to EBITDA 2.68 0.88 0.96

Dividend

Metric DSGN PRME Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric DSGN PRME Biotechnology median
Market cap 655.86m 654.77m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack